Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
General Findings of Adverse Event Reports
There are few direct comparisons of DMARDs in children with JIA, and the evidence is insufficient to determine if there are differential rates of adverse effects between drugs or drug classes.
Reported rates of adverse effects are similar between DMARDs and placebo in nearly all published randomized controlled trials. Adverse event rates may be underestimated by clinical trials that exclude patients because of adverse effects in a run-in phase.
The evidence about adverse effects has not been collected or reported systematically in patients with JIA.
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatoid arthritis | JCA | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | TNF-alpha blockers | biologic DMARD | nonbiologic DMARD | non-biologic DMARD | adverse effects
- Kemper A, Coeytaux R, Sanders G, et al. Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA). Comparative Effectiveness Review No. 28 (Prepared by the Duke Evidence-based Practice Center under Contract No. HHSA 290-2007-10066-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11-EHC039-EF. Available at www.effectivehealthcare.ahrq.gov/dmardsjia.cfm.
Your slide tray is being processed.